Microbiotica, Genentech in microbiome deal

Genentech Inc. partnered with Microbiotica Ltd. (Cambridge, U.K.) to discover targets and therapeutics for inflammatory bowel disease (IBD) using Microbiotica’s precision metagenomics microbiome platform.

Microbiotica will analyze patient samples from the Roche (SIX:ROG; OTCQX:RHHBY) unit’s clinical trials in ulcerative colitis and Crohn's disease to identify markers in the microbiome that indicate drug response, new microbiome targets and live bacterial therapeutic products...